# ACS APPLIED BIO MATERIALS

www.acsabm.org

Article

# Design of Thermoplastic Polyurethanes with Conferred Antibacterial, Mechanical, and Cytotoxic Properties for Catheter Application

<sup>4</sup> Rana Al Nakib, Antoniya Toncheva, Veronique Fontaine, Jérôme Vanheuverzwijn, Jean-Marie Raquez,\* <sup>5</sup> and Franck Meyer\*



s appropriate mechanical parameters and confirmed antibacterial and 9 cytocompatible properties. For this purpose, a series of quaternary 10 ammonium salts (QASs) and quaternary phosphonium salts (QPSs) 11 based monomers were prepared followed by the determination of their 12 minimal inhibitory concentrations (MICs) against Gram-positive *Staph*-13 *ylococcus aureus* (*S. aureus*) and Gram-negative *Pseudomonas aeruginosa* (*P.* 14 *aeruginosa*). A combination of the most active ammonium (QAS-C<sub>14</sub>) and 15 phosphonium (QPS-TOP) salts led to a MIC down to 2.4  $\mu$ g/mL against *S.* 16 *aureus* and 9  $\mu$ g/mL against *P. aeruginosa*, corroborating the existence of a 17 synergistic effect. These quaternary onium salt (QOS) units were



18 successfully incorporated along the polymer chain, as part of a two-step synthesis approach. The resulting **TPU-QOS** materials 19 were subsequently characterized through thermal, mechanical, and surface analyses. **TPU-Mix** (combining the most active **QAS-C**<sub>14</sub> 20 and **QPS-TOP** units) showed the highest antibacterial efficiency, confirming the synergistic effect between both **QOS** groups. 21 Finally, an MTT assay on the SiHa cell line revealed the low cytotoxicity level of these polymeric films, making these materials 22 suitable for biomedical application. To go one step further in the preindustrialization approach, proof of concept regarding the 23 catheter prototype fabrication based on **TPU-QAS/QPS** was validated by extrusion.

24 KEYWORDS: biomaterials, biomedical applications, polyurethane, antibacterial, onium salts, catheter

# 25 INTRODUCTION

26 For years now, bacterial infections have represented a major 27 health concern, responsible for severe complications difficult to 28 cure in clinical practice, as alerted by the World Health 29 Organization and governmental authorities.<sup>1,2</sup> In historical 30 context, since the 1940s, antibiotics have been introduced on a 31 large scale for the treatment of microbial infections. However, 32 their misuse led to a significant rise in antibiotic-resistant 33 bacteria, making the situation even more challenging.<sup>3</sup> As a 34 consequence, Hospital/Healthcare-Acquired Infections 35 (HAIs), namely acquired infections after hospital admission, 36 have emerged as an adverse outcome accompanied by 37 prolongating hospitalization and increasing the related patient 38 costs.<sup>4,5</sup> Medical implantable medical devices, such as 39 catheters, are known to be a subject of operative contam-40 ination, accounting for a large proportion of HAIs.<sup>6,7</sup> To 41 address this issue, the fabrication of biocompatible biomaterials 42 with conferred antimicrobial, anti-inflammatory, and/or 43 antifouling properties is subject to intense research from the 44 scientific community.<sup>8</sup> In this context, different concepts and 45 designs were proposed for the fabrication of catheters with incorporated bioactive agents that can be subsequently 46 released such as silver ions, antibiotics, nitric oxide, triclosan, 47 chlorhexidine, and others.<sup>9</sup> However, the leaching of cytotoxic 48 species into the patient's body arises as a major drawback. The 49 second option consists of the fabrication of surface-modified 50 materials, aiming to kill the microorganisms, thus suppressing 51 the development of biofilms on contact. Although antimicro- 52 bial enzymes are active against specific pathogens, their 53 production costs and denaturation appear detrimental.<sup>10</sup> 54 Ionic species like quaternary ammonium salts (**QASs**)<sup>11</sup> and 55 zwitterionic species represent another class of very effective 56 antibacterial agents.<sup>12,13</sup> In this vein, quaternary phosphonium 57 salts (**QPSs**) demonstrate much higher biocidal properties 58 with broader spectrum compared to their **QAS** counter-

Received: June 8, 2022 Accepted: October 28, 2022



60 parts.<sup>14,15</sup> This enhanced antibacterial activity is probably due 61 to the larger radius of the phosphorus atom that induces a 62 stronger polarization effect, facilitating the **QPS** adsorption on 63 a negatively charged bacterial cell wall.<sup>16,17</sup> However, in 64 contrast to the other ionic family members, fewer works 65 investigated the preparation of antibacterial **QPS**-based 66 surfaces.<sup>18</sup>

Based on the daily clinical problematic context and the need 67 68 of new biomaterials with desired properties, the possibility to 69 fabricate biocompatible thermoplastic polyurethanes (TPUs) 70 with incorporated onium salt units for potential catheter 71 application was explored. The TPU synthetic pathway was 72 studied in order to fine-tune the working conditions and obtain 73 materials with specific composition and optimal final 74 physicomechanical and biological properties. Therefore, a 75 range of TPUs was developed with a great range of mechanical <sup>76</sup> properties. After the successful incorporation of the active <sup>77</sup> agents (0.5 mol %),<sup>19</sup> their antibacterial and cytotoxicity 78 properties were studied. Additionally a mixture of QAS/QPS 79 in an appropriate molar ratio was tested for the synergistic 80 effect once incorporated in the TPU matrix.<sup>20</sup> It can be noted 81 that antibacterial agents combining ammonium and phospho-82 nium groups remain very rare in the literature.<sup>21,22</sup>

# 83 RESULTS AND DISCUSSION

84 For the successful fabrication of the **TPU**-based catheter, a 85 series of quaternary onium salts (**QOSs**) were first synthesized. 86 As a next step, it was of importance to fine-tune the **TPU** 87 physicomechanical properties by taking into account the 88 synthesis conditions and the monomers' molar ratio in order 89 to achieve the materials expected application properties. 90 Prototype feasibility of the catheter was also studied.

**Synthesis of Quaternary Onium Salts.** The preparation of polymerizable **QOSs** was performed from 3-bromopropane-1,2-diol (**Br-diol**) in the presence of varied tertiary amines or phosphines (Figure 1). These compounds possess short and long alkyl chains (from methyl to hexadecyl) and aryl functional groups for a phosphorus derivative. Indeed, it is well established that positively charged molecules can interact with the negatively charged domains of the bacterial cell wall,



Figure 1. Synthesis of quaternary onium salts (QOSs).

whereas long alkyl chains can interact with the bacterial wall 99 and disrupt its architecture.<sup>23</sup> Hence, quaternization of 100 nitrogen of trimethylamine, *N*,*N*-dimethyloctan-1-amine, 101 *N*,*N*-dimethyltetradecan-1-amine, *N*,*N*-dimethylhexadecan-1- 102 amine, and trioctylamine by **Br-diol** in refluxing ethanol gave 103 rise to the corresponding quaternary ammonium salts, namely 104 **QAS-C**<sub>1</sub>, **QAS-C**<sub>8</sub>, **QAS-C**<sub>14</sub>, **QAS-C**<sub>16</sub>, and **QAS-TOA** with 105 78 to 90% yields, respectively (Table 1). 106 til

Table 1. Reaction Yields of Prepared Quaternary Onium Salts

compound	starting amine or phosphine	reaction yield (%)
QAS-C <sub>1</sub>	N(CH <sub>3</sub> ) <sub>3</sub>	78
QAS-C <sub>8</sub>	$N(CH_3)_2(C_8H_{17})$	89
QAS-C <sub>14</sub>	$N(CH_3)_2(C_{14}H_{29})$	90
QAS-C <sub>16</sub>	$N(CH_3)_2(C_{16}H_{33})$	87
QAS-TOA	$N(C_8H_{17})_3$	86
QPS-Ph <sub>3</sub>	$P(C_6H_6)_3$	63
QPS-Bu <sub>3</sub>	$P(C_4H_9)_3$	72
QPS-TOP	$P(C_8H_{17})_3$	73

Under the same conditions, the reaction between triphenyl-, 107 tributyl-, and trioctylphosphine and **Br-diol** provided the 108 quaternary phosphonium salts, i.e., **QPS-Ph<sub>3</sub>**, **QPS-Bu<sub>3</sub>**, and 109 **QAS-TOP**, respectively, in 63 to 73% yields (Table 1). 110

Synthesis of Modified TPU. As far as the synthesis of 111 (modified) TPU is concerned, preliminary results confirmed 112 that a two-step polyaddition method was required to meet the 113 criteria to reach good physical properties of the materials. First, 114 a prepolymer was obtained through the reaction between 115 poly(tetrahydrofuran) (PTHF) and 4,4'-methylenebis(phenyl 116 isocyanate) (MDI) in a ratio of 1:2.2 in DMF at 90 °C. In the 117 second step, a mixture of a prepolymer, MDI, and 1,4-118 butanediol (BDO) employed in a ratio of 1:2.2:3 led to the 119 successful synthesis of TPU as a reference material - TPUr. 120 This strategy allowed the production of a polymer with desired 121 structural regularity, mechanical properties, and high molecular 122 weight  $(M_n \text{ of } 38 \text{ kDa})$ , as evidenced by gel permeation 123 chromatography (GPC). In a step further, the preparation of 124 modified TPU (TPU-QOS) incorporating ammonium (TPU- 125 QAS), phosphonium (TPU-QPS), or a mixture of ammo- 126 nium/phosphonium TPU-Mix active moieties was carried out 127 in two steps following the procedure described for the 128 formation of TPUr (Figure 2). In that case, ammonium 129 f2 and/or phosphonium units were introduced in the second step 130 of the reaction using only 0.5 mol % compared to the other 131 reagents. Hence, compounds TPU-QAS-C1, TPU-QAS-C8, 132 TPU-QAS-C<sub>14</sub>, TPU-QAS-C<sub>16</sub>, and TPU-QAS-TOA were 133 composed of ammonium units; TPU-QPS-Ph3, TPU-QPS- 134 Bu<sub>3</sub>, and TPU-QPS-TOP contained a phosphonium unit, 135 whereas TPU-Mix was prepared with an equimolar ratio of 136 QAS-C14/QPS-TOP targeting a potential synergistic anti- 137 bacterial effect (This choice will be explained in the section 138 relative to the antibacterial activity of QAS and QPS 139 monomers.). The modified polymers were isolated in good 140 reaction yields (up to 91%), with a molecular weight in the 141 range from 26 to 36 kDa, as determined by GPC analysis 142 (Table 2). The incorporation of about 0.5 mol % of the ionic 143 t2 species along the polymer macromolecular chain was addi- 144 tionally confirmed by <sup>1</sup>H NMR. 145

**Physical Characterization of TPU.** The obtained 146 materials were subjected to FT-IR spectroscopic analysis. For 147



Figure 2. Synthesis of modified TPU (TPU-QOS) incorporating an ammonium (TPU-QAS) or a phosphonium (TPU-QPS) unit or a mixture of QAS-C14/QPS-TOP in a 1:1 ratio.

Table 2. Chemical Composition, Reaction Yields, and $M_{\rm n}$ c	of
the Synthesized TPUr and TPU-QOS	

	TPU composition (molar ratio): PTHF (1)/MDI (4.4)/BDO/QOS			
compound	BDO	QOS (salt)	reaction yield (%)	$M_{ m n}$ (kDa)
TPUr	3	0	91	38
TPU-QAS-C1	2.96	$0.04 (QAS-C_1)$	90	36
TPU-QAS-C8	2.96	0.04 (QAS-C <sub>8</sub> )	89	32
TPU-QAS-C14	2.96	0.04 (QAS-C <sub>14</sub> )	90	30
TPU-QAS-C <sub>16</sub>	2.96	0.04 (QAS-C <sub>16</sub> )	91	27
TPU-QAS- TOA	2.96	0.04 (QAS-TOA)	88	29
TPU-QPS-Ph <sub>3</sub>	2.96	0.04 (QPS-Ph <sub>3</sub> )	87	26
TPU-QPS-Bu <sub>3</sub>	2.96	0.04 (QPS-Bu <sub>3</sub> )	90	27
TPU-QPS- TOP	2.96	0.04 (QPS-TOP)	91	29
TPU-Mix	2.96	0.02 (QAS-C <sub>14</sub> )+ 0.02 (QPS-TOP)	87	28

<sup>148</sup> all samples, the formation of urethane functionalities was <sup>149</sup> evidenced by the vanishing of the NCO characteristic band at <sup>150</sup> 2270 cm<sup>-1</sup> and the appearance of an absorption band at 3300 <sup>151</sup> cm<sup>-1</sup>, 1700–1730 cm<sup>-1</sup>, and 1450–1530 cm<sup>-1</sup>, characteristic <sup>152</sup> for N–H, C=O, and C–N bonds, respectively. In addition, the presence of other typical bands for MDI (C=C stretching 153 vibration at 1500–1700 cm<sup>-1</sup>), PTHF, and BDO (bending 154 vibration of C–H at 2850–2940 cm<sup>-1</sup> and C–O–C strong 155 absorption at 1100 cm<sup>-1</sup>) confirms the successful polymer-156 ization. As an example, FT-IR spectra of **TPUr**, **TPU-QAS-**157 C<sub>14</sub>, and **TPU-QPS-TOP** are presented in Figure 3. 158 f3

Thermal Analysis of TPU. It was of particular interest to 159 investigate the materials' thermal stability by thermogravi- 160 metric analysis (TGA), as well as the thermal transitions by 161 modulated differential scanning calorimetry (MDSC). TGA 162 obtained thermograms revealed three stages of thermal 163 degradation, where the greater weight loss was observed 164 during the first degradation temperature  $(T_d)$  taking place 165 around 300 °C (Figure 4). The  $T_d$ 's around 300–350 °C and 166 f4 400-450 °C are characteristic for urethane and ether 167 functional groups, respectively.<sup>24</sup> An exception is the TPU- 168 QAS<sub>14</sub> sample, where the weight loss at lower temperatures 169 (onset values around 100 °C) could be assigned to the lower 170 thermal stability of the samples and the occurrence of the 171 Hofmann elimination reaction of the quaternary ammonium 172 group, usually occurring at a temperatures higher than 150 173 °C.<sup>25</sup> In contrast, phosphonium groups are known to be stable 174 up to 300 °C.<sup>26</sup> For some of the specimens, a third  $T_{\rm d}$  was 175 observed around 550 °C. Overall, all compounds were 176 characterized with good thermal stability, making them suitable 177 for catheter application. 178



Figure 3. FT-IR spectra of TPUr (black), TPU-QAS-C14 (red), and TPU-QPS-TOP (blue).



Figure 4. TGA thermograms of TPUr and TPU-QOS and the corresponding derivative thermogravimetry (DTG) curves showing the decomposition rate.

<sup>179</sup> Based on the *MDSC* analysis, it was noticed that the glass <sup>180</sup> transition temperature ( $T_g$ ) of **TPU-QOS** increases, from -35 <sup>181</sup> to -10 °C, after the incorporation of the ammonium and phosphonium units. This can be explained with the greater 182 macromolecular chain mobility toward a greater degree of 183 order after the addition of the active moieties, as part of the 184



Figure 5. DSC thermograms (2nd heating cycle) of TPUr and TPU-QOS.

185 hard segment.<sup>27</sup> Thermal transitions relative to the materials 186 soft segment melting temperature  $(T_m)$  can be observed in the 187 range of 156 to 170 °C, explained with the high hard segment 188 content.<sup>28</sup> The decrease in  $T_m$  values, from 189 °C for TPUr 189 to 145 °C for TPU-QPS-TOP, was explained with the 190 addition of the ionic moieties, reflecting again the greater 191 polymer chains mobility and less thermally stable crystalline 192 domains (Figure 5). Both results related to the increase in  $T_g$ <sup>193</sup> and the decrease in the  $T_{\rm m}$  values after the incorporation of the 194 active moieties reflected the lower molecular weight as seen in 195 the GPC results for TPU-QOS.

Mechanical Tests of TPU. One of the most important 196 197 properties of the present materials is their physicomechanical 198 properties, presenting a key element for the TPU potential use 199 as catheters. Therefore, the synthesized materials subjected to 200 stress-strain tests are presented in Figure 6. The mean values 201 of the Young's modulus are presented in Figure 7. From the 202 obtained data it was concluded that the mechanical properties 203 of the TPU-based materials depended on the materials' 204 chemical composition, even at only 0.5 mol % of the 205 incorporated QOS. It was found that the incorporation of 206 QAS- $C_{14}$  presented an optimal solution to preserve the rigidity 207 of TPUr, while conferring biological properties: TPU-QAS-C14 Young's modulus was 302 MPa, slightly lower in values 208 compared to TPUr (324 MPa). 209

It is worth mentioning that Young's modulus lower values 210 211 were also obtained in the case of the incorporation of  $QAS-C_{11}$  $QAS-C_{8}$ , and  $QAS-C_{16}$ , but they are still in the acceptable 212 strength range for catheter designing (Figure 7).<sup>29</sup> 213

TPU-QAS-C<sub>14</sub> was characterized with a slightly low strain at 214 215 break (162%) compared to TPUr (230%), due to the lower 216 Mn of the TPU-QAS sample (Table 2). On the other hand, 217 the lower Young's values for TPU-QAS-C<sub>8</sub> were responsible 218 for the elastomeric properties of the material, where the strain 219 at break was 312%. TPU-QAS-C<sub>16</sub> presented lower strain at 220 break values (106%), in accordance with the low Young's 221 modulus value (116 MPa). In the case of the QPS 222 incorporation, a drop in the TPUs' Young's modulus was



Figure 6. Stress-strain curves of TPUr and TPU-QAS (up) and TPU-QPS and TPU-Mix (down).

also observed. However, the TPU-QPS-based materials were 223 still considered with suitable mechanical properties: the 224 obtained Young's modulus was 231 MPa, 175, and 162 MPa 225 for TPU-QPS-Ph<sub>3</sub>, TPU-QPS-Bu<sub>3</sub>, and TPU-QPS-TOP, 226 respectively. In this series of materials, only TPU-QPS-TOP 227 presented strain at break close to TPUr (250%), while TPU- 228 QPS-Ph3 and TPU-QPS-Bu3 had lower values: 162% and 229 208%, respectively. The obtained data were in accordance with 230 the lower Mn referenced to the TPU-QPS-based samples. 231

Article

f6

f7

www.acsabm.org



Figure 7. Young's modulus values of TPUr and TPU-QOS.



Figure 8. Contact angle values of TPUr and TPU-QOS.

232 From a materials point of view, it was promising to combine 233 the mechanical properties of TPU-QAS-C14 for its good 234 Young's modulus values and TPU-QPS-TOP for its good 235 elongation at break. Finally, the TPU-Mix sample presented 236 lower Young's modulus values (114 MPa) and increased 237 elongation at break (188%) compared to TPU-QAS-C<sub>14</sub>. In 238 accordance with the literature, TPU-QAS and TPU-QPS 239 presented slightly low mechanical properties due to the 240 presence of pendant groups, as referenced to TPUr.<sup>30</sup> The material DMTA results can be consulted in the SI (Figure S1). 241 When considering catheter application, two important 242 243 mechanical factors must be taken into consideration: 1) 244 flexibility of the material to ensure applicable and comfort 245 insertion and removal of the catheter and 2) material strength 246 to ensure the ability to withstand pressure during injection of 247 fluids. Kucinska-Lipka et al. studied the mechanical properties of neat and (1% and 2%) L-ascorbic acid-modified TPU 248 designed for medical applications.<sup>31</sup> The results of performed 249 250 studies showed a tensile strength between 7.5 and 6 MPa and 251 174% and 170% elongation at break.

Based on the findings presented above, the developed TPU-253 QOS-based materials present interesting mechanical proper-254 ties, competitive with the available and already used ones in 255 clinical practice materials. For example, intravenous catheters 256 present various mechanical properties as PVC catheters 257 (Vialon) are characterized with Young's modulus around 258 ~34 MPa and PVC- and Teflon-based catheters (FEP 100 Silastic) are characterized with Young's modulus values around 259  $\sim$ 25 MPa. Silicon catheters (Silastic), as soft material, have 260 Young's modulus around  $\sim$ 1.5 MPa, and PU materials (single- 261 lumen peripherally inserted central venous catheters) have 262 stiffness in the range from 14 to 74 MPa.<sup>32,29</sup> 263

Surface Analysis of TPU. Taking into account the 264 application field and the high-water content in living 265 organisms, we evaluated the contact angle of the materials. 266 The measurements confirmed the hydrophobicity of the 267 synthesized TPU-QAS, and values of 80° were obtained for 268 TPUr and slightly increased for TPU-QAS (values between 90 269 and 150°), due to the presence of the alkyl chain in the QAS 270 chemical structure (Figure 8). Surface analysis of TPU-QPS 271 f8 revealed angle values  $(80-100^\circ)$  close to TPUr. TPU-Mix 272 presented similar to the reference specimen angle values  $(80^\circ)$ . 273 In a recent work, a TPU having the Tecoflex composition, 274 namely TPU used for catheter fabrication, showed a contact 275 angle value of 92°.<sup>33</sup>

X-ray photoelectron spectroscopy (XPS) analysis of the  $^{277}$  specimens (elemental surface composition) is presented in  $^{278}$  Table S2. The atom percentages for C, N, and O in the  $^{279}$  samples were in the following range: 58.82-68.96%, 1.31-280 3.02%, and 21.11-25.61%, respectively (The presence of P  $^{281}$  atoms was not detected with the used technique.). The **TPU**- $^{282}$  **QAS** deconvoluted C 1s spectra revealed a slight increase in  $^{283}$  the surface area characteristic for C–H/C–C bonds (285 eV)  $^{284}$  in comparison to **TPUr** (Figure S2). This surface enrichment  $^{285}$ 

286 with C-H/C-C bonds (direct impact of the QAS 287 incorporation) was responsible for the higher contact values 288 of the TPU-QAS samples. This effect was less pronounced in 289 the case of **TPU-QPS**. The incorporation of the active moieties 290 led to a decrease in the C-O-C/C-N (286 eV) and O=C-291 O (289 eV) bone specific surface area. In the case of **TPUs**-292 **QPS-Ph**<sub>3</sub> and **TPUs-QPS-Bu**<sub>3</sub>, the C-H/C-C and C-O-C/ 293 C-N bond surface areas in the deconvoluted XPS spectra 294 remained close in value to **TPUr**, explaining the close contact 295 values of the specimens.

**QOS Antibacterial Activities.** The antibacterial properties prof the synthesized active moieties, i.e., ammonium and phosphonium monomers, were first evaluated by determining their minimal inhibitory concentrations (MICs). The ionic compounds were tested against Gram-positive *Staphylococcus* and *Gram-negative Pseudomonas aeruginosa* (*P. aeruginosa*) bacteria (Table 3). These strains were selected

Table 3. MIC of the Synthesized Moieties of QOSs against *S. aureus* and *P. aeruginosa* 

	MIC ( $\mu g/mL$ )	
compound	S. aureus	P. aeruginosa
QAS-C <sub>1</sub>	>2500	>2500
QAS-C <sub>8</sub>	310	2500
QAS-C <sub>14</sub>	4.88	78
QAS-C <sub>16</sub>	<2.44	156
QAS-TOA	310	2500
QPS-Ph <sub>3</sub>	2500	>2500
QPS-Bu <sub>3</sub>	2500	>2500
QPS-TOP	39	1250
QPS-TOP+QAS-C <sub>14</sub>	2.4	9

303 considering S. aureus is one of the five most common causes of 304 hospital-acquired infections, while P. aeruginosa shows a high 305 resistance to many biocides.<sup>34</sup> Therefore, compounds able to 306 target these strains could be good candidates for antibacterial 307 catheter manufacturing. Concerning the QASs, the antibacte-308 rial effect was improved when the alkyl chain length increases, 309 as observed for QAS-C1 to QAS-C16.35 Hence, MIC values 310 drop from >2500 to 2.4  $\mu$ g/mL against S. aureus and 78  $\mu$ g/ 311 mL against P. aeruginosa (for QAS-C<sub>14</sub>). Interestingly, QAS-312 TOA and QAS-C<sub>8</sub> exhibit the same activity against both strains 313 (MIC = 310  $\mu$ g/mL against *S. aureus* and no activity against *P*. 314 aeruginosa). On the other hand, both QPS-Ph<sub>3</sub> and QPS-Bu<sub>3</sub> did not show any antibacterial activity (MIC > 2500  $\mu$ g/mL), 315 316 whereas QPS-TOP has a significant antibacterial effect against 317 S. aureus (MIC = 39  $\mu$ g/mL) and is inactive against P. 318 aeruginosa (MIC = 1250  $\mu$ g/mL). This slight difference of 319 activity between QAS and QPS could be attributed to the 320 molecular structure of the salts and the intrinsic properties of the quaternized atoms. Phosphorus has a larger atom radius 321 than nitrogen, and thus, it exhibits a lower electronegativity. As 322 aforementioned, QPSs are weaker associated cations and have 323 stronger polarization effect compared to QASs making their 324 а adsorption onto negatively charged bacterial membranes 325 easier.<sup>36,37</sup> From these results, **QOSs** show higher antibacterial 326 activity against Gram-positive bacteria than Gram-negative 327 328 ones, probably due to the existence of the phospholipid bilayer 329 on the latter one rendering them more difficult to penetrate.<sup>38</sup> Finally, the most active onium salts, namely QAS-C<sub>14</sub> and 330 331 QPS-TOP, were combined and dissolved in water. As a result, 332 their MIC reached 2.4  $\mu$ g/mL against S. *aureus* and 9  $\mu$ g/mL

against *P. aeruginosa*, corroborating the existence of a 333 synergistic effect. Indeed, **QAS** integrates through its hydro- 334 phobic tail (when the alkyl chain length is longer than C8) into 335 the lipid layers of the bacterial cell membrane and damages it 336 by forming pores and disrupting membrane functions.<sup>39</sup> **QPS**, 337 on the other hand, forms defects on the bacterial cell wall 338 leading to aberrant septation.<sup>39,40</sup> Therefore, when combining 339 these agents, **QAS** helps with creating pores into the surface, 340 due to its longer alkyl chain, and **QPS** becomes even more 341 potent due to the reduced cell permeability. **QAS-C**<sub>14</sub> and 342 **QPS-TOP** were thereby chosen for the preparation of **TPU-** 343 **Mix.** 

Contact Antibacterial Activity of TPU-QOS. Another 345 aspect to be evaluated was the TPU-QOS antibacterial activity 346 in a contact antimicrobial assay, as previously communicated.<sup>19</sup> 347 Indeed, these polymeric ionic compounds are expected to 348 possess a contact killing behavior toward both Gram-positive 349 and Gram-negative bacteria.<sup>15</sup> As the active moieties are 350 covalently bonded to the TPU, no growth inhibition is to be 351 expected when testing the films' antibacterial activity. Never- 352 theless, the number of surviving bacteria in this contact assay 353 decreased (Figure 9) concomitantly with the QAS alkyl chain 354 f9 length, in agreement with their specific antibacterial activity 355 (Table 4). Similarly, for QPSs, a slight antibacterial activity 356 t4 and surviving bacteria log reduction were only observed with 357 QPS-TOP, further stressing the importance of the alkyl chain 358 length. TPU-Mix revealed the most efficient antibacterial 359 activity (3 log CFU reduction) confirming the desired/aimed 360 synergistic effect between the two active moieties. This 361 antibacterial polymeric material exhibits high activity toward 362 both Gram-positive and Gram-negative bacteria compared to 363 efficient antibacterial materials used for biomedical applica- 364 tions.<sup>41-43</sup> The same hypothesis for the synergistic effect, as in 365 the case of the MIC, holds for these polymeric materials. For 366 short-chain salts, such as QPSs having a higher adsorption 367 potency, the antimicrobial activity relies solely on the positively 368 charged group coupling with the negatively charged bacterial 369 cell wall to disrupt membrane functions, to alter membrane 370 potential, to reduce protein activity, and to damage bacterial 371 DNA.<sup>44</sup> Whereas long-chain salts, such as QAS-C<sub>14</sub>, not only 372 can destabilize the bacteria cell wall through their positive 373 charges (yet lower than QPSs) but also can be inserted into 374 the bacterial membrane, resulting in physical disruption.<sup>23</sup> 375 Another hypothesis can be that in the TPU-Mix, QOS 376 distribution and/or availability could be improved compared 377 to other modified TPUs. However, no characterization test was 378 performed to verify this suggestion. 379

**Cytotoxicity Analysis.**  $IC_{50}$  Determination of Dissolved <sup>380</sup> Polymers. The IC<sub>50</sub> of **TPUr** and **TPU-QOS** (dissolved in <sup>381</sup> DMSO) was evaluated in an MTT assay after 24, 48, and 72 h <sup>382</sup> of incubation. The results of the cytotoxicity assay on the SiHa <sup>383</sup> cell line are shown in Figure S7, and the IC<sub>50</sub> values are listed <sup>384</sup> in Table 4 and Table S3. A dose-dependent decrease in <sup>385</sup> viability was similarly observed for all the samples. It is worth <sup>386</sup> mentioning that cationic carriers exhibit a toxic effect on cells. <sup>387</sup> They tend to disturb the cell membrane integrity and decrease <sup>388</sup> their metabolic activity. <sup>389</sup>

Therefore, a low amount of charged groups is advised to be 390 incorporated in polymers for the sake of cytocompatibil- 391 ity.  $^{45-47}$  A comparison of the IC<sub>50</sub> values indicated that the 392 inhibitory effect on cell proliferation is on the same order of 393 magnitude for all compounds. 394



Figure 9. Antibacterial activity of TPUr and TPU-QOS against S. aureus (top) and P. aeruginosa (bottom).

Table 4.  $IC_{50}$  Values of TPUr and TPU-QOS against the SiHa Cell Line

compound	$IC_{50}$ ( $\mu g/mL$ )
TPUr	17
TPU-QAS-C <sub>1</sub>	19
TPU-QAS-C <sub>8</sub>	11
TPU-QAS-C <sub>14</sub>	18
TPU-QAS-C <sub>16</sub>	15
TPU-QAS-TOA	26
TPU-QPS-Ph <sub>3</sub>	20
TPU-QPS-Bu <sub>3</sub>	19
TPU-QPS-TOP	22
TPU-Mix	22

The  $IC_{50}$  values proved that the synthesized salts are toxic to 396 the cells. However, once covalently incorporated in the 397 polymer this difficulty is overcome since the active moieties 398 are now part of the **TPU-QAS** polymer macromolecular chain. 399 Therefore, a cytotoxicity study on the polymer (in a solid 400 form) was subsequently performed.

401 *Cytotoxicity of Polymer Films.* The cytotoxic effect of 402 **TPUr** and **TPU-QOS** films was also studied on the SiHa cell 403 line for a 24-, 48-, or 72-h cell exposure, following a 24-h 404 preincubation in cell culture medium. This procedure was 405 realized in accordance with ISO 10993-5. Afterward, an MTT 406 tetrazolium assay was carried out to determine the % cell 407 viability after exposure to the ionic compounds compared to 408 control samples. Materials are usually defined as toxic when 409 cell viability is reduced by more than 30% and slightly toxic for 410 values between 60% and 90%.<sup>48</sup> The formazan product 411 reflecting the number of living SiHa cells had slightly decreased after 24 and 48 h compared to the control (Figure 10). After 412 f10 72 h, about 80% of cell viability was observed without a 413 significant difference between the polymeric compounds. 414 **TPU-QOS** thus demonstrated a slight cytotoxicity reaching 415 an acceptable value for biomedical application in comparison 416 with other biomaterials.<sup>49,50</sup> 417

Having the **QOSs** covalently bonded to the polymer and in a 418 very low percentage probably helps to maintain a low 419 cytotoxicity level, leading to a safe material for biomedical 420 applications. According to the available literature, latex urinary 421 catheters are considered highly toxic.<sup>51</sup> A study done by Ruutu 422 et al. brought to attention the highly toxic effect of the latex 423 catheter eluate on various human cell cultures.<sup>52</sup> Additionally, 424 Pariente et al. advised removing the latex used in catheters 425 after proving their high toxicity on human urothelial cells for 426 both indirect and direct contact tests.<sup>53</sup>

**Catheter Fabrication.** As a final step, catheter prototype 428 fabrication based on the most promising compound **TPU-Mix** 429 was carried out through an extrusion process (parallel twinscrew extruder), as described in our previous study.<sup>19</sup> Based on 431 the morphological analysis, the resulting material presented a 432 homogeneous compact polymer matrix and confirmed the 433 thermal stability (absence of color change and thermo-434 oxidative degradation) and the processing feasibility of the 435 material (Figure 11). 436 fill

Further tests on the catheter should be performed in the 437 presence of human blood in order to evaluate blood cell 438 viability, adhesion, and coagulation impact. An additive 439 manufacturing approach, such as fused deposition modeling 440 – 3D printing, should additionally be explored for the concept 441 and design of personalized catheters with complex shapes for 442 implants with antibacterial and cytocompatibility properties. 443



Figure 10. Percentage of cell viability of SiHa cells after being exposed 24, 48, and 72 h to TPUr and TPU-QOS.



Figure 11. Digital photo and SEM micrograph of the TPU-Mix prototype catheter.

### 444 CONCLUSIONS

445 In summary, TPUs endowed with suitable mechanical, 446 antibacterial, and cytotoxic properties for potential catheter 447 application were designed. A series of modified polymeric 448 materials were obtained, containing ammonium and/or 449 phosphonium salt units as antibacterial agents. The resulting 450 stress-strain curves evidenced mechanical properties com-451 petitive with the available on the market catheters already used 452 in clinical practice, making the TPU-QOS suitable for the 453 required application. Moreover, the materials demonstrated 454 good thermal stability and  $T_{\rm m}$  far above 100 °C, making them 455 acceptable for sterilization procedures in clinical practice. In 456 addition to the material hydrophobic characteristics, their 457 antibacterial behavior against Gram-positive S. aureus and Gram-negative P. aeruginosa was confirmed by incorporating 458 only 0.5 mol % of the QAS and QPS in the polymer. The 459 combination of QAS-C<sub>14</sub> and QPS-TOP acted synergistically, 460 461 leading to a MIC lower than 9  $\mu$ g/mL against both strains. This trend was corroborated through contact antimicrobial 462 463 assays of corresponding polymers. A comparison of TPUr and 464 TPU-QOS confirmed that the presence of onium units bearing 465 long alkyl chains dramatically decreased the number of living S. 466 aureus and P. aeruginosa. Moreover, TPU-Mix (combining 0.5 467 mol % of QAS-C14 and QPS-TOP units) had the most 468 efficient antibacterial activity, confirming the synergistic effect 469 between the two active onium groups. Finally, an MTT assay

on the SiHa cell line confirmed the low cytotoxicity level of 470 **TPUr** and **TPU-QOS** films, making these polymers suitable 471 materials for biomedical application. First prototypes were also 472 developed revealing the great potential of the proposed 473 polymer systems. With the present research, combining 474 polymer synthesis and processing techniques and materials 475 biological evaluation, an ambitious multidisciplinary solution 476 was proposed to go one step further in the fabrication of next 477 generation biologically active biomaterials, such as personal- 478 ized biocompatible catheters.

# EXPERIMENTAL METHODS

Materials. The following compounds were used: poly- 481 (tetrahydrofuran) (PTHF, 1000 g/mol, Merck), 4,4'-methylenebis- 482 (phenylisocyanate) (MDI, 250.25 g/mol, Alfa-Aesar), 1,4-butanediol 483 (BDO, 90.12 g/mol, Sigma-Aldrich), N,N-dimethylformamide anhy- 484 drous (DMF, Sigma-Aldrich), 1,1-dimethylethylenediamine (amine, 485 88.15 g/mol), 3-bromo-1,2-propanediol 97% (Br-diol, 154.99 g/mol, 486 Sigma-Aldrich), 2-(dimethylamino)ethyl acrylate (acrylate, 143.18 g/ 487 mol, Sigma-Aldrich), trimethylamine (TMA, 59.11 g/mol, Sigma- 488 Aldrich), N,N-dimethyloctylamine (DMOA, 157.30 g/mol, Sigma- 489 Aldrich), trioctylamine (TOA, 353.67 g/mol, Sigma-Aldrich), N,N- 490 dimethyltetradecylamine (DMTDA, 241.46 g/mol, Sigma-Aldrich), 491 N,N-dimethylhexadecylamine (DMHDA, 269.51 g/mol, Sigma- 492 Aldrich), tributylphosphine (TBP, 202.32 g/mol, Sigma-Aldrich), 493 triphenylphosphine (TPP, 262.29 g/mol, Sigma-Aldrich), trioctyl- 494 phosphine (TOP, 370.64 g/mol, Sigma-Aldrich), 1-bromo-3-propanol 495 (138.99 g/mol, Sigma-Aldrich), and 2,2-bis(bromomethyl)-1,3- 496

480

497 propandiol (261.94 g/mol, Sigma-Aldrich). Acetonitrile (ACN), 498 ethanol (EtOH), methanol (MeOH), dichloromethane (DCM), 499 acetone, tryptic soy broth (TSB), and Mueller-Hinton broth 500 (MHB) were purchased from VWR. All materials were used as-501 received without further purification.

**Characterization.** <sup>1</sup>H NMR and Fourier transform infrared (FT-503 IR) spectroscopies, thermal gravimetric analysis (TGA), modulated 504 differential scanning calorimetry (MDSC), X-ray diffraction (XRD), 505 dynamic mechanical thermal analysis (DMTA), and X-ray photo-506 electron spectroscopy (XPS) analyses were carried out using 507 equipment and conditions previously reported. <sup>19,54,55</sup>

**Synthesis.** Synthesis of **QOSS.** QASs were prepared through the 509 reaction of Br-diol (1.2 equiv) with TMA, DMOA, TOA DMTDA, or 510 DMHDA. The reaction was carried out at 80 °C for 48 h in absolute 511 ethanol. After cooling, the mixture was poured in diethyl ether, 512 leading to the precipitation of the salt. The resulting compound was 513 filtered off and dried to give QAS-C<sub>1</sub>, QAS-C<sub>8</sub>, QAS-TOA, QAS-C<sub>14</sub>, 514 and QAS-C<sub>16</sub>. Likewise, QPSs were synthesized using Br-diol (1.2 515 equiv) with TBP, TPP, or TOP, under the same conditions; however, 516 the reaction was kept running for 72 h at 60 °C in bulk producing 517 QPS-Bu<sub>3</sub>, QPS-Ph<sub>3</sub>, and QPS-TOP.

<sup>518</sup> <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.26 (m, -CH-), 3.65-3.42 (m, 519 -CH<sub>2</sub>-), 3.22 (s, N-CH<sub>3</sub>), 1.22 (m, -CH<sub>2</sub>-), 0.87 (t, *J* = 6.8 Hz, 520 -CH<sub>3</sub>).

<sup>521</sup> 3-(*Trimethyl-λ<sup>4</sup>-azaneyl*)propane-1,2-diol Bromide (**QAS-C**<sub>1</sub>). <sup>1</sup>H <sup>522</sup> NMR (500 MHz, CDCl<sub>3</sub>): δ 3.94 (m, -CH-), 3.77-3.49 (m, <sup>523</sup> -CH<sub>2</sub>-), 2.86 (s, -CH<sub>3</sub>).

<sup>524</sup> *N-(2,3-Dihydroxypropyl)-N,N-dimethyloctan-1-aminium Bro-*<sup>525</sup> *mide* (*QAS-C<sub>g</sub>*). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.99 (s, –OH), <sup>526</sup> 4.48 (s, –OH), 4.40 (m, –CH–), 3.74–3.67 (m, –CH<sub>2</sub>–), 3.50 (m, <sup>527</sup> N–CH<sub>3</sub>), 3.30 (s, –CH<sub>3</sub>), 1.74 (m, –CH<sub>2</sub>–), 1.33 (m, –CH<sub>2</sub>–), <sup>528</sup> 0.85 (m, –CH<sub>3</sub>).

<sup>529</sup> *N-(2,3-Dihydroxypropyl)-N,N-dioctyloctan-1-ide-1-aminium* <sup>530</sup> Bromide (**QAS-TOA**). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.26 (m, <sup>531</sup> -CH-), 3.65-3.42 (m, -CH<sub>2</sub>-), 3.22 (m, -CH<sub>2</sub>-), 1.22 (m, <sup>532</sup> -CH<sub>2</sub>-), and 0.83 (m, -CH<sub>3</sub>).

533 *N*-(**2**,**3**-Dihydroxypropyl)-N,*N*-dimethyltetradecan-1-ammonium 534 Bromide (**QAS-C**<sub>14</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.26 (m, 535 -CH-), 3.65-3.42 (m, -CH<sub>2</sub>-), 3.22 (s, N-CH<sub>3</sub>), 1.22 (m, 536 -CH<sub>2</sub>-), 0.87 (t, *J* = 6.8 Hz, -CH<sub>3</sub>).

<sup>537</sup> 1-((2,3-Dihydroxypropyl)dimethyl-l4-azaneyl)hexadecane-pen-<sup>538</sup> tadecaylium Bromide (**QAS-C**<sub>16</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$ <sup>539</sup> 5.09 (s, -OH), 4.95 (s, -OH), 3.80 (m, -CH-), 3.69-3.51 (m, <sup>540</sup> -CH<sub>2</sub>-), 3.34 (s, -CH<sub>3</sub>), 1.74 (m, -CH<sub>2</sub>-), 1.24 (m, -CH<sub>2</sub>-), <sup>541</sup> 0.87 (m, -CH<sub>3</sub>).

542 2,3-(Dihydroxypropyl)triphenylphosphonium Bromide (**QPS**-543 **Ph**<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.77 (m, –CH-arom), 7.66 544 (m, –CH-arom), 4.05 (m, –CH<sub>2</sub>–), 3.83–3.72 (m, P-CH<sub>2</sub>), and 545 3.44 (m, –CH–).

546 2,3-(Dihydroxypropyl)tributylphosphonium Bromide (**QPS-Bu**<sub>3</sub>). 547 <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.26 (m, -CH-), 3.70 (m, 548 -CH<sub>2</sub>-), 2.64 (m, -CH<sub>2</sub>-), 2.33 (m, P-CH<sub>2</sub>), 2.53 (m, -CH<sub>2</sub>-), 549 and 0.97 (m, -CH<sub>3</sub>).

550 2,3-(Dihydroxypropyl)trioctylphosphonium Bromide (**QPS-TOP**). 551 <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  4.24 (s, OH), 3.93 (m, -CH<sub>2</sub>-), 552 3.72-3.67 (m, -CH-), 3.47-2.62 (m, -CH<sub>2</sub>-), 2.30 (m, -CH<sub>2</sub>-553 P), 1.25 (m, -CH<sub>2</sub>-), and 0.87 (m, -CH<sub>3</sub>).

Synthesis of **TPUr**. **TPUr** was synthesized using PTHF/MDI/ S55 BDO in a ratio of 1/4.4/3, respectively. In the first step, PTHF (3 g; 3 S56 mmol) was solubilized in DMF (28 mL; 25% w/v) followed by S57 dropwise addition of MDI (1.65 g; 6.59 mmol). The reaction was S58 heated at 90 °C for 2 h. In the second step, MDI (1.65 g; 6.59 mmol) S59 and BDO (0.8 g; 8.87 mmol) were added to the stirring solution, and S60 the reaction was kept at 90 °C for 3 h.

At the end of the reaction, the solvent was evaporated using a 562 ventilated oven overnight at 60  $^{\circ}$ C, followed by 12 h of drying in a 563 vacuum oven at 60  $^{\circ}$ C. For purification, Soxhlet extraction was carried 564 out for 48 h at 40  $^{\circ}$ C using chloroform as a solvent.

565 Size exclusion chromatography was performed under conditions 566 identical to those previously reported.<sup>19</sup> <sup>1</sup>H NMR (500 MHz, THF- $d_8$ ):  $\delta$  8.59 (s, -NHC=O), 7.35-7.02 567 (m, H arom.), 4.12 (m, COOCH<sub>2</sub>), 3.82 (s, Ar-CH<sub>2</sub>-Ar), 3.36 (m, 568 -CH<sub>2</sub>-O), and 1.58 (m, -CH<sub>2</sub>). 569

www.acsabm.org

FTIR (in cm<sup>-1</sup>): 3300 (N–H), 2940–2850 (C–H), 1730–1700 570 (C=O), 1600 (C–N), 1550–1500 (C=C), and 1100 (C–O–C). 571

Synthesis of **TPU-QOS**. QOS-containing **TPUs** were synthesized 572 following the synthesis path of **TPUr**. QOSs were incorporated in the 573 second step giving **TPU-QOS**, and the yields and  $M_n$  were measured. 574

*Typical Procedure: TPU-QAS-C*<sub>14</sub>, TPU-QAS-C<sub>14</sub> was synthesized 575 using PTHF/MDI/BDO/QAS-C<sub>14</sub> in a molar ratio of 1/4.4/2.96/576 0.04, respectively. In the first step, PTHF (3 g; 3 mmol) was 577 solubilized in DMF (28 mL; 25% w/v) followed by dropwise addition 578 of MDI (1.65 g; 6.59 mmol). The reaction was heated at 90 °C for 2 579 h. In the second step, MDI (1.65 g; 6.59 mmol), BDO (0.8 g; 8.87 580 mmol), and QAS-C<sub>14</sub> (0.047 g; 0.118 mmol) were added to the 581 stirred solution, and the reaction was kept at 90 °C for 3 h.

**TPU-QAS-C**<sub>1</sub>. <sup>1</sup>H NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  9.5 (s, -NHC= 583 O), 7.33-7.07 (m, H arom.), 4.09 (m, COOCH<sub>2</sub>), 3.88 (s, Ar- 584 CH<sub>2</sub>-Ar), 3.4 (m, -CH-), 3.35 (m, O-CH<sub>2</sub>), 1.69-1.48 (m, CH<sub>2</sub>), 585 1.29 (m, CH<sub>2</sub>), and 0.85 (m, CH<sub>3</sub>). 586

**TPU-QAS-C**<sub>8</sub>. <sup>1</sup>H NMR (500 MHz, THF- $d_8$ ):  $\delta$  8.81 (s, -NHC= 587 O), 7.37-7.03 (m, H arom.), 4.13 (m, COOCH<sub>2</sub>), 3.88 (s, Ar- 588 CH<sub>2</sub>-Ar), 3.4 (m, -CH-), 3.35 (m, O-CH<sub>2</sub>), 1.69-1.48 (m, CH<sub>2</sub>), 589 1.29 (m, CH<sub>2</sub>), and 0.85 (m, CH<sub>3</sub>). 590

**TPU-QAS-TOA.** <sup>1</sup>H NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  9.91 (s, 591 –NHC=O), 7.34–7.07 (m, H arom.), 4.44 (m, –CH–), 4.08 (m, 592 COOCH<sub>2</sub>), 3.82 (s, Ar–CH<sub>2</sub>–Ar), 3.37 (m, –CH<sub>2</sub>–), 1.58 (m, 593 CH<sub>2</sub>), 1.22 (m, CH<sub>2</sub>), and 0.84 (m, CH<sub>3</sub>).

**TPU-QAS-C**<sub>14</sub>. <sup>1</sup>H NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  9.5 (s, 595 –NHC=O), 8.5 (s, -NHC=O), 7.33, 7.07 (m, H arom.), 4.09 596 (m, COOCH<sub>2</sub>), 3.88 (s, Ar–CH<sub>2</sub>–Ar), 3.4 (m, –CH–), 3.35 (m, 597 O–CH<sub>2</sub>), 1.69–1.48 (m, CH<sub>2</sub>), 1.29 (m, CH<sub>2</sub>), and 0.85 (m, CH<sub>3</sub>). 598

**TPU-QAS-C**<sub>16</sub>. <sup>1</sup>H NMR (500 MHz, THF- $d_8$ ):  $\delta$  8.69 (s, -NHC = 599 O), 7.37-7.03 (m, H arom.), 4.12 (m, COOCH<sub>2</sub>), 3.82 (s, Ar- 600 CH<sub>2</sub>-Ar), 3.72 (m, -CH-), 3.58 (m, O-CH<sub>2</sub>), 3.37 (m, CH<sub>2</sub>), 1.58 601 (m, CH<sub>2</sub>), 1.28 (m, CH<sub>2</sub>), and 0.85 (m, CH<sub>3</sub>). 602

**TPU-QPS-Ph3.** <sup>1</sup>H NMR (500 MHz, THF- $d_8$ ):  $\delta$  8.64 (s, -NHC= 603 O), 7.67-7.60 (m, H arom.), 7.37-7.03 (m, H arom.), 4.12 (m, 604 COOCH<sub>2</sub>), 3.82 (s, Ar-CH<sub>2</sub>-Ar), 3.72 (m, -CH-), 3.24 (m, CH<sub>2</sub>), 605 2.6 (m, CH<sub>2</sub>), and 1.36 (m, CH<sub>3</sub>). 606

**TPU-QPS-Bu3.** <sup>1</sup>H NMR (500 MHz, THF- $d_8$ ):  $\delta$  8.62 (s, -NHC= 607 O), 7.36-7.04 (m, H arom.), 4.12 (m, COOCH<sub>2</sub>), 3.93 (m, CH<sub>2</sub>), 608 3.76 (s, Ar-CH<sub>2</sub>-Ar), 3.36 (m, -CH-), 3.23 (m, O-CH<sub>2</sub>), 2.95 609 (m, CH<sub>2</sub>), 2.56 (m, CH<sub>2</sub>), 1.46 (m, CH<sub>2</sub>), and 0.95 (m, CH<sub>3</sub>). 610

**TPU-QPS-TOP.** <sup>1</sup>H NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  9.49–8.50 (s, 611 –NHC=O), 7.33–7.07 (m, H arom.), 4.09 (m, COOCH<sub>2</sub>), 3.77 (s, 612 Ar-CH<sub>2</sub>-Ar), 3.33 (m, -CH<sub>2</sub>-), 3.29 (m, CH<sub>2</sub>), 1.48 (m, CH<sub>2</sub>), 613 1.23 (m, CH<sub>2</sub>), and 0.85 (m, CH<sub>3</sub>). 614

**TPU-Mix.** <sup>1</sup>H NMR (500 MHz, DMSO- $d_{\delta}$ ):  $\delta$  9.52–8.53 (s, 615 –NHC=O), 7.35–7.08 (m, Ar–H), 3.77 (s, Ar–CH<sub>2</sub>–Ar), 4.09 (m, 616 O–CH<sub>2</sub>–, 8H), 3.34 (m, O–CH–), 3.6 (s, –CH<sub>3</sub>–), 1.97 (m, P-617 CH<sub>2</sub>–), 1.48–1.69 (m, –CH<sub>2</sub>–), 1.23 (m, –CH<sub>2</sub>–), and 0.85 (m, 618 –CH<sub>3</sub>).

Biological Tests. Minimum inhibitory concentration (MIC), 620 contact antibacterial activity of polymers, and  $IC_{50}$  determination of 621 polymers were determined through the procedures described in a 622 previous study.<sup>19</sup> Catheter prototyping. The catheter fabrication was 623 performed through extrusion according to the procedure described in 624 a previous study.<sup>19</sup> 625

# ASSOCIATED CONTENT

## **Supporting Information**

. The Supporting Information is available free of charge at 628 https://pubs.acs.org/doi/10.1021/acsabm.2c00531. 629

Additional experimental details: Thermal values of TPUr and TPU-QOS; C, O, and N elemental percentages of TPUr and TPU-QOS; Evaluation of % cell viability and IC<sub>50</sub> of synthesized TPU at different

626

627

693

695

concentrations; E' (storage modulus), E'' (loss mod-634 ulus), and Tan  $\delta$  of TPUr (black), TPU-QAS-C<sub>14</sub> 635 (blue), and TPU-QPS-TOP (red); Deconvoluted C1 636 spectra of TPUr and TPU-QOS; MIC of QPS-TOP, 637 Tween 80, and TPUr (control negative) against Gram-638 positive and Gram-negative bacteria; MIC of QAS-C14 639 and TPUr against Gram-positive and Gram-negative 640 bacteria; Evaluation of % cell viability of synthesized 641

TPU at different concentrations (PDF) 642

#### AUTHOR INFORMATION 643

#### **Corresponding Authors** 644

Jean-Marie Raquez – Laboratory of Polymeric and Composite 645

Materials, University of Mons, Faculty of Science, 7000 Mons, 646

- Belgium; o orcid.org/0000-0003-1940-7129; Email: jean-647
- marie.raquez@umons.ac.be 648
- Franck Meyer Microbiology, Bioorganic and 649
- Macromolecular Chemistry Unit, Université libre de Bruxelles 650

(ULB), Faculty of Pharmacy, 1050 Bruxelles, Belgium; 651

- orcid.org/0000-0002-8028-0609; Email: franck.meyer@ 652
- ulb.be 653

# 654 Authors

- Rana Al Nakib Laboratory of Polymeric and Composite 655
- Materials, University of Mons, Faculty of Science, 7000 Mons, 656

Belgium; Microbiology, Bioorganic and Macromolecular 657

- 658 Chemistry Unit, Université libre de Bruxelles (ULB), Faculty of Pharmacy, 1050 Bruxelles, Belgium 659
- Antoniya Toncheva Laboratory of Polymeric and 660
- Composite Materials, University of Mons, Faculty of Science, 661
- 7000 Mons, Belgium; Laboratory of Bioactive Polymers, 662
- Institute of Polymers, Bulgarian Academy of Sciences, 1113 663 Sofia, Bulgaria 664
- Veronique Fontaine Microbiology, Bioorganic and 665
- Macromolecular Chemistry Unit, Université libre de Bruxelles 666 (ULB), Faculty of Pharmacy, 1050 Bruxelles, Belgium 667
- Jérôme Vanheuverzwijn Microbiology, Bioorganic and 668
- Macromolecular Chemistry Unit, Université libre de Bruxelles 669 (ULB), Faculty of Pharmacy, 1050 Bruxelles, Belgium 670

# 671 Complete contact information is available at:

672 https://pubs.acs.org/10.1021/acsabm.2c00531

# 673 Author Contributions

674 Conceptualization, F.M. and J.-M.R.; methodology, F.M., J.-675 M.R., R.A.N., J.V., A.T., and V.F.; validation, F.M., J.-M.R., 676 A.T., and V.F.; formal analysis, F.M., J.-M.R., R.A.N., J.V., A.T., 677 and V.F.; investigation, F.M., J.-M.R., R.A.N., J.V., A.T., and 678 V.F.; resources, F.M., J.-M.R., A.T., and V.F.; data curation, 679 F.M., J.-M.R., R.A.N., J.V., A.T., and V.F.; writing-original 680 draft preparation, F.M., J.-M.R., A.T., and V. F; writing-681 review and editing, F.M. and J.-M.R.; supervision, F.M. and J.-682 M.R.; project administration, F.M. and J.-M.R.; funding 683 acquisition, J.-M.R.

## 684 Funding

685 The research was financially supported by the PROSTEM 686 project, the COST action CA15114 "AMiCI" (Antimicrobial 687 Coating Innovations to Prevent Infectious Diseases), and the 688 COST action TD1305 "iPROMEDAI" (Improved PROtection 689 of MEdical Devices Against Infection). SMPC is grateful to the 690 Region Wallonne support in the case of LCFM-BIOMAT.

### 691 Notes

692 The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

J.M.R. is a senior research associate at FRS-FNRS. 694

REFERENCES

(1) WHO. Global action plan on antimicrobial resistance; WHO: 696 Geneva, 2015. https://www.amcra.be/swfiles/files/ 697 WHO%20actieplan\_90.pdf (accessed 2022-08-11). 698

(2) European Commission. One Health Action Plan against 699 Antimicrobial Resistance; 2017. https://ec.europa.eu/health/sites/ 700 default/files/antimicrobial\_resistance/docs/amr\_2017\_action-plan. 701 pdf (accessed 2022-08-11). 702

(3) Cassini, A.; Högberg, L. D.; Plachouras, D.; Quattrocchi, A.; 703 Hoxha, A.; Simonsen, G. S.; Colomb-Cotinat, M.; Kretzschmar, M. E.; 704 Devleesschauwer, B.; Cecchini, M.; et al. Attributable Deaths and 705 Disability-Adjusted Life-Years Caused by Infections with Antibiotic- 706 Resistant Bacteria in the EU and the European Economic Area in 707 2015 : A Population-Level Modelling Analysis. Lancet Infect. deseases 708 2019, 19, 56-66. 709

(4) Sydnor, E. R. M.; Perl, T. M. Hospital Epidemiology and 710 Infection Control in Acute-Care Settings Hospital Epidemiology and 711 Infection Control in Acute-Care Settings. Clin. Microbiol. Rev. 2011, 712 24. 141-173. 713

(5) Liu, L.; Shi, H.; Yu, H.; Yana, S.; Luan, S. The Recent Advances 714 in Surface Antibacterial Strategies for Biomedical Catheters. Biomater. 715 Sci. 2020, 8, 4095-4108. 716

(6) Gahlot, R.; Nigam, C.; Kumar, V.; Yadav, G.; Anupurba, S. 717 Catheter-related Bloodstream Infections. Int. J. Crit. Illn. Inj. Sci. 2014, 718 4. 161-167. 719

(7) Neoh, K. G.; Li, M.; Kang, E.-T.; Chiong, E.; Tambyah, P. A. 720 Surface Modification Strategies for Combating Catheter-Related 721 Complications Recent Advances and Challenges. J. Mater. Chem. B 722 2017, 5, 2045-2067. 723

(8) Zhang, L.; Gowardman, J.; Rickard, C. M. Impact of Microbial 724 Attachment on Intravascular Catheter-Related Infections. Int. J. 725 Antimicrob. Agents 2011, 38 (1), 9-15. 726

(9) Singha, P.; Locklin, J.; Handa, H. A Review of the Recent 727 Advances in Antimicrobial Coatings for Urinary Catheters. Acta 728 Biomater. 2017, 50, 20-40. 729

(10) Al-Qahtani, M.; Safan, A.; Jassim, G.; Abadla, S. Efficacy of 730 Anti-Microbial Catheters in Preventing Catheter Associated Urinary 731 Tract Infections in Hospitalized Patients: A Review on Recent 732 Updates. J. Infect. Public Health 2019, 12 (6), 760-766. 733

(11) Druvari, D.; Koromilas, N. D.; Bekiari, V.; Bokias, G.; Kallitsis, 734 J. K. Polymeric Antimicrobial Coatings Based on Quaternary 735 Ammonium Compounds. Coatings 2018, 8, 8. 736

(12) Jiang, B. S.; Cao, Z. Ultralow-Fouling, Functionalizable, and 737 Hydrolyzable Zwitterionic Materials and Their Derivatives for 738 Biological Applications. Adv. Mater. 2010, 22, 920-932. 739

(13) Colilla, M.; Izquierdo-Barba, I.; Vallet-Regi, M. The Role of 740 Zwitterionic Materials in the Fight against Proteins and Bacteria. 741 Medicines 2018, 5, 125. 742

(14) Kanazawa, A.; Ikeda, T.; Endo, T. Novel Polycationic Biocides: 743 Synthesis and Antibacterial Activity. J. Polym. Sci. Part A Polym. Chem. 744 Sci. Part A 1993, 31, 335-343. 745

(15) Xue, Y.; Xiao, H.; Zhang, Y. Antimicrobial Polymeric Materials 746 with Quaternary Ammonium and Phosphonium Salts. Int. J. Mol. Sci. 747 **2015**, 16 (2), 3626–3655. 748

(16) Li, L.; Zhou, H.; Gai, F.; Chi, X.; Zhao, Y.; Zhang, F.; Zhao, Z. 749 Synthesis of Quaternary Phosphonium N-Chloramine Biocides for 750 Antimicrobial Applications. RSC Adv. 2017, 7 (22), 13244–13249. 751 (17) Xue, Y.; Pan, Y.; Xiao, H.; Zhao, Y. Novel Quaternary 752 Phosphonium-Type Cationic Polyacrylamide and Elucidation of 753 Dual-Functional Antibacterial/Antiviral Activity. RSC Adv. 2014, 4, 754 46887-46895. 755

(18) Cuthbert, T. J.; Harrison, T. D.; Ragogna, J.; Gillies, E. R. 756 Synthesis, Properties, and Antibacterial Activity of Polyphosphonium 757 Semi-Interpenetrating Networks. J. Mater. Chem. B 2016, 4, 4872- 758 4883. 759

(19) Al Nakib, R.; Toncheva, A.; Fontaine, V.; Vanheuverzwijn, J.;
Raquez, J. M.; Meyer, F. Thermoplastic Polyurethanes for Biomedical
Application: A Synthetic, Mechanical, Antibacterial, and Cytotoxic
Study. J. Appl. Polym. Sci. 2022, 139 (4), 51666.

764 (20) Kanazawa, A.; Ikeda, T.; Endo, T. Polymeric Phosphonium 765 Salts as a Novel Class of Cationic Biocides. VIII. Synergistic Effect on 766 Antibacterial Activity of Polymeric Phosphonium and Ammonium 767 Salts. J. Appl. Polym. Sci. **1994**, 53, 1245–1249.

768 (21) Popa, A.; Ilia, G.; Iliescu, S.; Dehelean, G. Mixed Quaternary
769 Ammonium and Phosphonium Salts Bound to Macromolecular
770 Supports for Removal Bacteria from Water. *Mol. Cryst. Liq. Cryst.*771 2004, 418, 195–203.

772 (22) Brunel, F.; Lautard, C.; Garzino, F.; Raimundo, J.-M.; Bolla, J.-

773 M.; Camplo, M. Phosphonium- Ammonium- Based Di- Cationic 774 Ionic Liquids as Antibacterial over the ESKAPE Group. *Bioorg. Med.* 775 *Chem. Lett.* **2020**, *30*, 127389.

776 (23) Li, F.; Weir, M. D.; Xu, H. H. K. Effects of Quaternary 777 Ammonium Chain Length on Antibacterial Bonding Agents. *J. Dent.* 778 *Res.* **2013**, *92* (10), 932–938.

779 (24) Trovati, G.; Sanches, E. A.; Neto, S. C.; Mascarenhas, Y. P.; 780 Chierice, G. O. Crystallization Behavior of  $Poly(\epsilon$ -Caprolactone)/ 781 Layered Double Hydroxide Nanocomposites. *J. Appl. Polym. Sci.* 782 **2010**, 115 (1), 263–268.

783 (25) Zhuravlev, O. E.; Nikol'skii, V. M.; Voronchikhina, L. I. 784 Thermal Stability of Quaternary Ammonium Hexafluorophosphates 785 and Halides. *Russ. J. Appl. Chem.* **2013**, *86* (6), 824–830.

(26) Hemp, S. T.; Zhang, M.; Allen, M. H.; Cheng, S.; Moore, R. B.;
Zong, T. E. Comparing Ammonium and Phosphonium Polymerized
Ionic Liquids: Thermal Analysis, Conductivity, and Morphology. *Macromol. Chem. Phys.* 2013, 214 (18), 2099–2107.

790 (27) Wu, C. H.; Shau, S. M.; Liu, S. C.; Dai, S. A.; Chen, S. C.; Lee, 791 R. H.; Hsieh, C. F.; Jeng, R. J. Enhanced Shape Memory Performance 792 of Polyurethanes via the Incorporation of Organic or Inorganic 793 Networks. *RSC Adv.* **2015**, 5 (22), 16897–16910.

794 (28) Kébir, N.; Nouigues, S.; Moranne, P.; Burel, F. Nonisocyanate
795 Thermoplastic Polyurethane Elastomers Based on Poly(Ethylene
796 Glycol) Prepared through the Transurethanization Approach. J. Appl.
797 Polym. Sci. 2017, 134 (45), 44991.

798 (29) Lambert, J. M.; Lee, M. -S; Taller, R. A.; Solomon, D. D. 799 Medical Grade Tubing: Criteria for Catheter Applications. *J. Vinyl* 800 *Technol.* **1991**, *13* (4), 204–207.

(30) Bakhshi, H.; Yeganeh, H.; Mehdipour-Ataei, S.; Shokrgozar, M.
A.; Yari, A.; Saeedi-Eslami, S. N. Synthesis and Characterization of
Antibacterial Polyurethane Coatings from Quaternary Ammonium
Salts Functionalized Soybean Oil Based Polyols. *Mater. Sci. Eng., C*2013, 33 (1), 153–164.

806 (31) Kucinska-Lipka, J.; Gubanska, I.; Sienkiewicz, M. Thermal and 807 Mechanical Properties of Polyurethanes Modified with L-Ascorbic 808 Acid. J. Therm. Anal. Calorim. **2017**, *127* (2), 1631–1638.

809 (32) Poli, P.; Scocca, A.; Di Puccio, F.; Gallone, G.; Angelini, L.; 810 Calabrò, E. M. A Comparative Study on the Mechanical Behavior of 811 Polyurethane PICCs. J. Vasc. Access **2016**, 17 (2), 175–181.

812 (33) Peng, C.; Vishwakarma, A.; Li, Z.; Miyoshi, T.; Barton, H. A.;
813 Joy, A. Modification of a Conventional Polyurethane Composition
814 Provides Significant Anti-Biofilm Activity against Escherichia Coli.
815 Polym. Chem. 2018, 9, 3195–3198.

816 (34) McDonnell, G.; Russell, D. A. Antiseptics and Disinfectants: 817 Activity, Action, and Resistance. *Clin. Microbiol. Rev.* **1999**, *12*, 147– 818 179.

(35) Ji, W.; Koepsel, R. R.; Murata, H.; Zadan, S.; Campbell, A. S.;
Russell, A. J. Bactericidal Specificity and Resistance Profile of
Poly(Quaternary Ammonium) Polymers and Protein-Poly(Quaternary Ammonium) Conjugates. *Biomacromolecules* 2017, 18

823 (8), 2583–2593.
824 (36) Kurt, P.; Wood, L.; Ohman, D. E.; Wynne, K. J. Highly
825 Effective Contact Antimicrobial Surfaces via Polymer Surface
826 Modifiers. *Langmuir* 2007, 23 (9), 4719–4723.

827 (37) Venkataraman, S.; Zhang, Y.; Liu, L.; Yang, Y. Y. Design, 828 Syntheses and Evaluation of Hemocompatible Pegylated-Antimicrobial Polymers with Well-Controlled Molecular Structures. Biomaterials 829

www.acsabm.org

**2010**, *31* (7), 1751–1756. 830 (38) Zhang, Y.; He, W.; Li, J.; Wang, K.; Li, J.; Tan, H.; Fu, Q. 831 Gemini Quaternary Ammonium Salt Waterborne Biodegradable 832 Polyurethanes with Antibacterial and Biocompatible Properties. 833 *Mater. Chem. Front.* **2017**, *1* (2), 361–368. 834

(39) Nikitina, E. V.; Zeldi, M. I.; Pugachev, M. V.; Sapozhnikov, S. 835 V.; Shtyrlin, N. V.; Kuznetsova, S. V.; Evtygin, V. E.; Bogachev, M. I.; 836 Kayumov, A. R.; Shtyrlin, Y. G. Antibacterial Effects of Quaternary 837 Bis-Phosphonium and Ammonium Salts of Pyridoxine on Staph-838 ylococcus Aureus Cells: A Single Base Hitting Two Distinct Targets? 839 *World J. Microbiol. Biotechnol.* **2016**, 32 (1), 1–7. 840

(40) Zeng, W.; He, J.; Liu, F. Preparation and Properties of 841 Antibacterial ABS Plastics Based on Polymeric Quaternary 842 Phosphonium Salts Antibacterial Agents. *Polym. Adv. Technol.* **2019**, 843 30 (10), 2515–2522. 844

(41) Liu, Z.; Chen, C.; Jiang, R.; Zhao, J.; Ren, L. Shape Memory 845 Composite Film for Bacteria Killing and Biofilm Detaching. *Mater.* 846 *Lett.* 2021, 286, 129186. 847

(42) Hasanzadeh, A.; Gholipour, B.; Rostamnia, S.; Eftekhari, A.; 848 Tanomand, A. Biosynthesis of AgNPs onto the Urea-Based Periodic 849 Mesoporous Organosilica (Ag x NPs/Ur-PMO) for Antibacterial and 850 Cell Viability Assay. J. Colloid Interface Sci. 2021, 585, 676–683. 851

(43) Cai, D.; Zhao, X.; Yang, L.; Wang, R.; Qin, G.; Chen, D. fu; 852 Zhang, E. A Novel Biomedical Titanium Alloy with High Antibacterial 853 Property and Low Elastic Modulus. *J. Mater. Sci. Technol.* **2021**, *81*, 854 13–25. 855

(44) Simoncic, B.; Tomsic, B. Structures of Novel Antimicrobial 856 Agents for Textiles - A Review. *Text. Res. J.* **2010**, 80 (16), 1721–857 1737. 858

(45) Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In 859 Vitro Cytotoxicity Testing of Polycations: Influence of Polymer 860 Structure on Cell Viability and Hemolysis. *Biomaterials* **2003**, *24*, 861 1121–1131. 862

(46) Stratton, T. R.; Rickus, J. L.; Youngblood, J. P. In Vitro 863 Biocompatibility Studies of Antibacterial Quaternary Polymers. 864 *Biomacromolecules* **2009**, *10* (9), 2550–2555. 865

(47) Stratton, T. R.; Howarter, J. A.; Allison, B. C.; Applegate, B. M.; 866 Youngblood, J. P. Structure - Activity Relationships of Antibacterial 867 and Biocompatible Copolymers. *Biomacromolecules* **2010**, *11*, 1286–868 1290. 869

(48) International Organization for Standadization. ISO 10993-5. 870 Biological evaluation of medical devices- Part 5: Tests for in vitro 871 cytotoxicity; ISO: Geneva, 2009. 872

(49) Miao, S.; Sun, L.; Wang, P.; Liu, R.; Su, Z.; Zhang, S. Soybean 873 Oil-Based Polyurethane Networks as Candidate Biomaterials: Syn- 874 thesis and Biocompatibility. *Eur. J. Lipid Sci. Technol.* **2012**, *114* (10), 875 1165–1174. 876

(50) Guelcher, S.; Srinivasan, A.; Hafeman, A.; Gallagher, K.; 877 Doctor, J.; Khetan, S.; Bride, S. M. C.; Hollinger, J. Synthesis, In Vitro 878 Degradation, and Mechanical Properties of Two-Component Poly- 879 (Ester Urethane) Urea Scaffolds: Effects of Water and Polyol 880 Composition. *Tissue Eng.* **2007**, *13* (9), 2321–2333. 881

(51) Talja, M.; Anderson, L. C.; Ruutu, M.; Alfthan, O. Toxicity 882 Testing of Urinary Catheters. *Br. J. Urol.* **1985**, 57 (5), 579–584. 883

(52) Ruutu, M.; Alfthan, O.; Talja, M.; Anderson, L. C. Cytotoxicity 884 of Latex Urinary Catheters. Br. J. Urol. **1985**, 57 (1), 82–87. 885 (53) Pariente, J. L.; Bordenave, L.; Jacob, F.; Bareille, R.; Baquey, C.; 886

Le Guillou, M. Cytotoxicity Assessment of Latex Urinary Catheters 887 on Cultured Human Urothelial Cells. *Eur. Urol.* **2000**, *38* (5), 640–888 643.

(54) Meyer, F.; Raquez, J. M.; Verge, P.; Martínez De Arenaza, I.; 890 Coto, B.; Van Der Voort, P.; Meaurio, E.; Dervaux, B.; Sarasua, J. R.; 891 Du Prez, F.; Dubois, P. Poly(Ethylene Oxide)-b-Poly(1 -Lactide) 892 Diblock Copolymer/Carbon Nanotube-Based Nanocomposites: LiCl 893 as Supramolecular Structure-Directing Agent. *Biomacromolecules* 894 **2011**, *12* (11), 4086–4094. 895

(55) Meyer, F.; Raquez, J. M.; Coulembier, O.; De Winter, J.; 896 Gerbaux, P.; Dubois, P. Imidazolium End-Functionalized Poly(1- 897

www.acsabm.org

898 Lactide) for Efficient Carbon Nanotube Dispersion. *Chem. Commun.*899 2010, 46 (30), 5527–5529.